GB2360089A - Diagnostic assay for transmisible spongiform encephalopathies - Google Patents
Diagnostic assay for transmisible spongiform encephalopathies Download PDFInfo
- Publication number
- GB2360089A GB2360089A GB0005683A GB0005683A GB2360089A GB 2360089 A GB2360089 A GB 2360089A GB 0005683 A GB0005683 A GB 0005683A GB 0005683 A GB0005683 A GB 0005683A GB 2360089 A GB2360089 A GB 2360089A
- Authority
- GB
- United Kingdom
- Prior art keywords
- fabp
- assay
- ami
- antibody
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000003556 assay Methods 0.000 title claims abstract description 44
- 208000024777 Prion disease Diseases 0.000 title claims description 7
- 102000011026 Fatty Acid Binding Protein 3 Human genes 0.000 claims abstract description 44
- 108010062715 Fatty Acid Binding Protein 3 Proteins 0.000 claims abstract description 44
- 102000002140 Fatty Acid-Binding Protein 7 Human genes 0.000 claims abstract description 4
- 108010001387 Fatty Acid-Binding Protein 7 Proteins 0.000 claims abstract description 4
- 102100037733 Fatty acid-binding protein, brain Human genes 0.000 claims abstract 3
- 101710098548 Fatty acid-binding protein, brain Proteins 0.000 claims abstract 3
- 238000000034 method Methods 0.000 claims description 23
- 208000010544 human prion disease Diseases 0.000 claims description 8
- 210000002966 serum Anatomy 0.000 claims description 6
- 230000001154 acute effect Effects 0.000 claims description 5
- 210000004369 blood Anatomy 0.000 claims description 4
- 239000008280 blood Substances 0.000 claims description 4
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 claims description 4
- 210000001124 body fluid Anatomy 0.000 claims description 3
- 239000010839 body fluid Substances 0.000 claims description 3
- 230000002107 myocardial effect Effects 0.000 claims description 3
- 229960003624 creatine Drugs 0.000 claims description 2
- 239000006046 creatine Substances 0.000 claims description 2
- 238000003118 sandwich ELISA Methods 0.000 claims description 2
- 101100226596 Gallus gallus FABP gene Proteins 0.000 claims 1
- 206010061216 Infarction Diseases 0.000 claims 1
- 230000007574 infarction Effects 0.000 claims 1
- 206010000891 acute myocardial infarction Diseases 0.000 abstract description 45
- 239000003550 marker Substances 0.000 abstract description 12
- 238000003018 immunoassay Methods 0.000 abstract description 9
- 102000004190 Enzymes Human genes 0.000 abstract description 4
- 108090000790 Enzymes Proteins 0.000 abstract description 4
- 102000030914 Fatty Acid-Binding Human genes 0.000 description 27
- 108091022862 fatty acid binding Proteins 0.000 description 27
- 239000000523 sample Substances 0.000 description 13
- 102000013394 Troponin I Human genes 0.000 description 11
- 108010065729 Troponin I Proteins 0.000 description 11
- 238000003745 diagnosis Methods 0.000 description 9
- 206010012289 Dementia Diseases 0.000 description 8
- 210000004556 brain Anatomy 0.000 description 7
- 238000005406 washing Methods 0.000 description 7
- 238000001514 detection method Methods 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- 101001027663 Homo sapiens Fatty acid-binding protein, heart Proteins 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 102000047025 human FABP3 Human genes 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 102000004899 14-3-3 Proteins Human genes 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- NGSWKAQJJWESNS-UHFFFAOYSA-N 4-coumaric acid Chemical compound OC(=O)C=CC1=CC=C(O)C=C1 NGSWKAQJJWESNS-UHFFFAOYSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 2
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 2
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000723543 Homo sapiens 14-3-3 protein theta Proteins 0.000 description 2
- 102100030856 Myoglobin Human genes 0.000 description 2
- 108010062374 Myoglobin Proteins 0.000 description 2
- 102000029797 Prion Human genes 0.000 description 2
- 108091000054 Prion Proteins 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 238000011888 autopsy Methods 0.000 description 2
- 239000003150 biochemical marker Substances 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000011859 microparticle Substances 0.000 description 2
- 238000000424 optical density measurement Methods 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 101710112812 14-3-3 protein Proteins 0.000 description 1
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
- VSMDINRNYYEDRN-UHFFFAOYSA-N 4-iodophenol Chemical compound OC1=CC=C(I)C=C1 VSMDINRNYYEDRN-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000004420 Creatine Kinase Human genes 0.000 description 1
- 108010042126 Creatine kinase Proteins 0.000 description 1
- 206010018341 Gliosis Diseases 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101001027674 Homo sapiens Fatty acid-binding protein, brain Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102100036859 Troponin I, cardiac muscle Human genes 0.000 description 1
- 101710128251 Troponin I, cardiac muscle Proteins 0.000 description 1
- 208000018756 Variant Creutzfeldt-Jakob disease Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000009833 antibody interaction Effects 0.000 description 1
- 239000013584 assay control Substances 0.000 description 1
- 208000037875 astrocytosis Diseases 0.000 description 1
- 230000007341 astrogliosis Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 208000005881 bovine spongiform encephalopathy Diseases 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 230000003683 cardiac damage Effects 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000007435 diagnostic evaluation Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- KAKKHKRHCKCAGH-UHFFFAOYSA-L disodium;(4-nitrophenyl) phosphate;hexahydrate Chemical compound O.O.O.O.O.O.[Na+].[Na+].[O-][N+](=O)C1=CC=C(OP([O-])([O-])=O)C=C1 KAKKHKRHCKCAGH-UHFFFAOYSA-L 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 201000006061 fatal familial insomnia Diseases 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 102000045058 human FABP7 Human genes 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 206010023497 kuru Diseases 0.000 description 1
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000007121 neuropathological change Effects 0.000 description 1
- 238000007474 nonparametric Mann- Whitney U test Methods 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 208000008864 scrapie Diseases 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000000954 titration curve Methods 0.000 description 1
- 238000000539 two dimensional gel electrophoresis Methods 0.000 description 1
- 238000001419 two-dimensional polyacrylamide gel electrophoresis Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2828—Prion diseases
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Heart and brain fatty acid binding proteins (H-FABP, B-FABP) are markers for TSEs, especially CJD. The invention provides a diagnostic assay for either of these markers, preferably by enzyme immunoassay using a specific antibody thereto. Since H-FABP is also a marker for acute myocardial infarction (AMI), to distinguish CJD from AMI requires an assay specific to AMI, e.g. using troponin-1 or CK-MB as a marker, also to be carried out.
Description
t 2360089
"DIAGNOSTIC ASSAY FOR TRANSMISIBLE SPONGIFORM ENCEPHALOPATHIES11 BACKGROUND OF THE IN TION Field of the invention
This invention is in the field of diagnostic assay using a protein or an antibody thereto. Description of the related art
Transmissible spongiform encephalopathies (TSEs) are neurodegenerative diseases of the central nervous system.
They can be transmitted, inherited or occur sporadically and are observed in animals, e.g. as bovine spongiform encephalopathy in cattle or scrapie in sheep, as well as in humans as Creutzfeldt-Jakob disease (CJD), Gerstman Str&ussler Scheinker syndrome, Fatal Familial Insomnia or is Kuru. They have a long incubation period, leading to ataxia, dementia, psychiatric disturbances and death. Neuropathological changes include vacuolar degeneration of brain tissue, astrogliosis and amylo:ld plaque formation. The diseases are difficult to diagnose pre- mortem.
The cerebrospinal fluid (CSF) of WD patients displays two additional polypeptide by two-dimensional polyacrylamide gel electrophoresis [Harrington, M.G. New England Journal of Medicine 315, 279 (1986), Hsich, G., Kenney, K., Gibbs, C.J., Lee, K.H. & Harrington, M. B. New England Journal of Medicine 335, 924 (1996)] The function of these 14-3-3 polypeptides rmain unclear in TSE. They can be used in a pre-mortem test for WD diagnostic evaluation, but have low specificity.
Monoclonal antibodies to the abnormal form of prion protein are available and can be used in an enzyme-lúnked immunoassay, as described in PCT Specifications WO 99/23962 and 98132710 and Schmerr, M.J., the Beckman
Coulter Pace Setter Newsletter 3 (2) 1-4 (June 1999), but these procedures have not yet been fully developed.
Development of new non-invaslve blood WD and BSE markers would help clinicians to establish early diagnosis. SUMARY OF THE INVENTION
It has now surprisingly been found that two fatty acid binding proteins (FABP), known as heart (H-FABP) and brain (B-FABP), are markers for TSEs. Thus, a TSE or the possibility thereof in a sample of body fluid taken from a patient suspected of suffering from the TSE, which comprises determining the concentration of heart or brain fatty acid binding protein (H-FABP or B- FABP) in the sample. the method is especially applicable to the is diagnosis of WD in human patients.
Conveniently the method is carried out using an antibody to H-FABP or BFABP, whereby the extent of the reaction between the antibody and the FABP in the sample is assayed and related to the concentration of FABP in the sample. The concentration thus determined is used to make or assist in making a diagnosis.
The present invention enables an assay of high sensitivity, specificity and predictive accuracy for WD to be carried out. "Sensitivity" is defined as the percentage of true positives given by the assay on samples taken from patients in whom clinical examination has confirmed WD. 11Speclficityll means the percentage of true negatives given by the assay on control samples, 1.e. from patients in whom clinical examination has not revealed WD. "Predictive accuracy" means the ratio of true positives to total positives (true + false) expressed as a percentage.
H-FABP is a known infaretion (AMI), see marker of acute Ishil, J. et al myocard.ial 1 "Serum 3 - is concentrations of myoglobin vs human heart-type cytoplasmic fatty-acid binding protein in early detection of acute myocardial infarctionll. Clinical Chemistry 1997;43 1372-1378. Therefore, in order to use an assay for H-FABP for the diagnosis of WD in humans to better advantage, it is desirable to perform another kind of assay for AMI (one in which the marker is not a FABP) in order to eliminate from the diagnosis for CiD those patients who are positive in the AMI assay.
Thus, in a particular embodiment, the invention provides a method which comprises determining the concentration of H-FABP in a first assay, as defined above, whereby a positive result indicates either a WD or acute myocardial infarction, and which further comprises carrying out a second diagnostic assay, for acute myocardial infarction (AMI) only, whereby a positive result in the H-FABP assay and a negative result in the assay for AMI indicates that the patient might be suffering from WD. Assays using Troponin-1 and Creatine Kinase-MB (CK-MB) as early biochemical markers of acute myocardial infarction (AMI) are well known and suitable for the above purpose.
A similar H-FABP and also a brain-specific fatty acid binding protein (BFABP) have been found in the brain of mice, see Pu, L. et al., Molecular and Cellular Biochemistry 198, 69-78 (1999). Brain H-FABP (not to be confused with B-FABP) is believed to differ from heart HFABP by a single amino acid substitution. However, BFABP differs considerably. Sellner, P.A. et al., it Development role of fatty acid binding proteins in mouse brain" Dev. Brain Res. 89, 33-46 (1995), estimated the DNA homology at 69%, while A. Schreiber et al., 11Recombinant human heart-type fatty acid binding protein as standard in immunochemIcal assays", Clin. Chem. Lab.
0 Med. 36(5), 283-288 (1998), mention 64% amino acid sequence homology and that a monoclonal antibody to human H-FABP is cross-reactive with human BFABP to the extent of only 1.7%.
Now that the present inventors have found that HFABP is a marker for CM, it is a very reasonable prediction that B-FABP will also be. Since B-FABP is specific to brain tissue and does not appear to react significantly with a monoclonal antibody to H-FABP, it will not give positives for AMI, making a separate assay for AMI unnecessary.
BRIEF DESCRIPTION OF THE DRAWINGS
The Figure is a graphic representation on the y-axis of H-FABP concentration represented by optical density is measurement at 405 nm, as determined by the method of the invention, for (a) a control group having neither CiD nor AMI (b) a group having AMI and (c) a group having CM.
DESCRIPTION OF PREFERRED EMBODIMENTS
For the method of assay, the sample can be taken from any convenient body fluid of the subject. The method is considered applicable to all types of TSE, including those referred to above, and to any human or animal suffering therefrom. The marker, H-FABP or BFABP, is preferably measured by an immunoassay, using a specific antibody to H- FABP and measuring the extent of the antigen (H-FABP or B-MBP) /antibody interaction. For the diagnosis of human patients, the antibody is preferably anti-human H-FABP or B-MBP. Similarly, if the patient is an animal the antibody should be to the H-FABP or B-FABP of the same animal variety, e.g. anti-bovine HFABP or B-FABP if the patient is bovine. It may be a monoclonal antibody or an engineered antibody. Conveniently a mouse anti-human, anti-bovine etc. (depending on the animal from which the sample to be is tested has been derived) monoclonal antibody is used. Antibodies to H- FABP are known, e.g. 66E2 and 67D3 described by Roos, W. et al., 11Monoclonal antibodies to human heart type fatty acid-binding protein", J. Immunol. Methods 183 149-153 (1995). Antibody 66E2 is commercially available. Also, the usual K6hler-Milstein method may be used to raise H- FABP or B-FABP antibodies. The source of protein for this purpose can be the naturally derived or recombinant DNA-prepared protein.
Recombinant human H-FABP and B-FABP have been described by Schrelber, A. supra and Shimizu, F. et al., "Isolation and expression of a cDNA for human brain fatty acid binding protein (B-FABP)11, Blochim Biophys. Acta 1354, 24-28 (1997), respectively. Less preferably, the antibody may be polyclonal.
Any known method of Immuncassay may be used. A sandwich assay is preferred. In this method, a first antibody to the FABP is bound to the solid phase such as a well of a plastics microtitre plate, and incubated with the sample and with a labelled second antibody specific to the H-FABP or B-FABP to be detected. Alternatively, an antibody capture assay could be used here, the test sample is allowed to bind to a solid phase, and the antiFABP antibody is then added and allowed to bind. After washing away unbound material, the presence or amount of antibody bound to the solid phase is determined using a labelled second antibody, anti- to the first.
In another embodiment, a competition assay could be performed between the sample and a labelled FABP or a peptide derived therefrom, these two antigens being in competition for a limited amount of anti-FABP antibody bound to a solid support. The labelled FABP or peptide could be pre-Incubated with the antibody on the solid 6 - phase, whereby the FABP in the sample displaces part of the FABP or peptide thereof bound to the antibody.
In yet another embodiment, the two antigens are allowed to compete in a single co-incubation with the antibody. After removal of unbound antigen from the support by washing, the amount of label attached to the support is determined and the amount of protein in the sample is measured by reference to standard titration curves established previously.
The label is preferably an enzyme. The substrate for the enzyme may be colour-forming, fluorescent or chemiluminescent.
It is highly preferable to use an amplified form of assay, whereby an enhanced ""signal.' is produced from a is relatively low level of protein to be detected. One particular form of amplified immunoassay Is enhanced chem! luminescent (ECL) assay. Here, the antibody is preferably labelled with horseradish peroxidase, which participates in a chemiluminescent reaction with luminol, a peroxide substrate and a compound which enhances the intensity and duration of the emitted light, typically 4iodophenol or 4-hydroxycinnamic acid.
Another preferred form of amplified immunoassay is imm,iino-PCR. In this technique, the antibody is covalently linked to a molecule of arbitrary DNA comprising PCR primers, whereby the DNA with the antibody attached to it is amplified by the polymerase chain reaction. See Hendrickson, E.R. et al., Nucleic Acids Research 23, 522-529 (1995) or Sano, T. et al., in "'Molecular Biology and Biotechnology" ed. Robert A. Meyers, VCH Publishers, Inc. (1995), pages 458 - 460. The signal is read out as before.
In a particularly preferred procedure, an enzymelinked immunosorbent assay (ELISA) was developed to 7 - detect H-FABP in serum. Since H-FABP is a marker for AMI as well, Troponin-1 or CK-MB levels were assayed in order to exclude any heart damage. As described in the Example, these assays were assessed in serial plasma and CSF samples, from patients lacking AMI and WD, patients with AMI patients with dementia and patients with confirmed WD through autopsy. The sensitivity, specúfIcity and predictive accuracy for H-FABP in WD above a suitable cut-off level were all 100%. Thus, H- FABP detection combined with the Troponin-I or CK-MB assay provides a useful serum marker of WD diagnosis or brain damage.
The use of a rapid microparticle-enhanced turb:LcL-Imetric immunoassay, developed for H-FABP in the is case of AMI, Robers, M. et al., "Development of a rapid microparticle- enhanced turbldlmetric immunoassay for plasma fatty acid-binding protein, an early marker of acute myocardial infarctionll, Clin. Chem. 44, 1564- 1567 (1998), should drastically decrease the tIme, of the assay. Thus, the full automation in a widely used clinical chemistry analyser such as the COBASTM MIRA Plus system from Hoffmann-La Roche or the AxSYWm system from Abbott laboratories should be possible and applied for routine clinical diagnosis of WD.
The H-FABP or B-FABP can be measured by other means than immunoassay. For example, the sample can be subjected to 1 or 2-DE gel electrophoresis and the amount of the FABP estimated by densItometric scanning of the gel or of a blot therefrom.
The assay of the invention can be used together with one or more other pre-mortem assays for the TSE, including specifically those assays described above. Such combined procedures are particularly useful in diagnosing BSE in cattle.
The following Example illustrates the invention. EXAMPLE Materials And Methods Patients The study population consisted of 3 age-and-gender matched control patients (Control group), 3 confirmed AMI patients (AMI group), 3 confirmed dementia patients (dementia group) and 3 confirmed WD patients (WD group). The Control group included 2 men, mean age 66, range 46-86 years, and 1 woman, age 63 years. The AMI group included 2 men, mean age 65, range 40-90 years, and 1 woman, age 72 years. The dementia group included 2 men, mean age 65, range 43-87 years, and 1 women, age 64 years. The WD group included 2 men, mean age 68, range 62-74 years, and 1 woman, age 65. Blood and CSF samples were collected for each patient of the WD. Blood samples were collected in dry heparin-containing tubes. After centrifugation at 1500g for 15min at 40C, tubes were stored at -200C until analysis. Patients from the WD group underwent serial clinical evaluations by neurologists in order to confirm WD diagnosis. Patients from the AMI group were admitted to the hospital with a conf Irmed AMI (Troponin-I concentration >2ng/m1). A clinical evaluation was performed on all the patients from the control group to exclude WD and AMI.
Measurement of brain and heart H-FABP H-FABP levels were measured in plasma by a sandwich ELISA. A 96-well polystyrene microplate (NUNC) was coated with 100pl/well goat anti human- FABP, detecting all isoforms (Spectral Diagnosis HC, Ontario, USA), 20.4ng/ml in carbonate buffer 0.1M pH 9.6, overnight at 40C. The plate was automatically washed with PBS (15mM Na2P04-12OmM NaCI-2.7mM KCl pH 7.4, Sigma) on a BioRad NOVAPATH' washer. Every washing step was performed with fresh PBS.
Non-spec fic binding sites were blocked with 200pl/well 2% casein in carbonate buffer for 2h at 3VC. After the washing step, the samples were pipetted in duplicate at 100pl/well. The plate was incubated 2h at 370C. After the washing step, 100pl/well of mouse ant:i-human Heart FABP (clone 66E2, By,Cult Biotechnology BV, Uden, Netherlands), 0.3ng/ml in PBS-1%BSA, were incubated for 1h at room temperature (R.T) with shaking. After the washing step, 100pl/well of phosphatase-labelled anti-mouse immunoglobulin (Dako, Denmark), 15ng/ml in PBS, were incubated 1h 30min at R.T. with shaking. After the washing step, 501A/well of phosphatase substrate, I.Smg/ml para-nitrophenylphosphate in diethanolamine was added and the samples were then incubated for 30min. The is reaction was stopped with 100pl/well IM NaOH. Colour development was measured with a microplate reader at a wavelength of 405nm. CK-MB and Troponin-I measurement AMI was diagnosed by clinical evaluation and Troponin-I and CK-MB measurements. Samples were centrifuged at 1500g for 15min, and stored at -20'C.
Serum CK-MB and Troponin-I levels were determined using a fluorescent microparticle enzyme immunoassay (MEIA) with an automated chemical analyser AxSYW" system (Abbott Laboratories, Abbott Park, IL, USA). The rate of formation of fluorescent products was directly proportional to the amount of Troponin-I in the sample.
The detection limit for TroponIn-I was 0.3pg/1. CK-MB measurement is proportional to the amount of fluorescent probes and the detection limit was 0.7pg/1.
Statistical analysis H-FABP levels were expressed in optical densitometry (M) values either as mean SD or as median and inter- quartile range. Troponin-I and CK-MB levels were - 10 expressed in concentration units (ng/ml). The nonparametric Mann-Whitney U-test and Kruskal-Wallis H-test were used to compare in plasma H-FABP, Troponin-I and CK- MB concentrations between groups. PRISM software was used to elaborate box/whisker and scatter plots. The 95% confidence intervals (CI) and Receiver Operating Characteristic (ROC) curves, defined by Analyse-itIlm software for Microsoft EXCEL", were used to assess the discriminatory time point of the indicators. See Murphy, J.M. et al., "Performance of screening and diagnostic tests", Arch. Gen. Psychiatry 44, 550-555 (1987).
P<0.05 was considered statistically significant. Results Clinical characteristics Patients from the WD group were given a complete clinical evaluation. WD was finally diagnosed with the help of brain immuno-histology after autopsy. Patients from the Control group were admitted to hospital and WD and AMI were excluded by clinical evaluation.
Patients from the AMI group were admitted to the hospital with confirmed AMI with high Troponin-I levels (>2ng/ml).
Assay results are shown in Table 1 below.
Assay Control AMI Dementia WD WD type Group Group Group Group Group plasma plasma CSF plasma CSF H-FABP median 0.25 2.89 0.20 0.79 0.46 (25-75%) (0.23- (2.70- (0.16- (0.74- (0.38- OD, 405 nm 0.27) 3.0) 0.31) 0.86) 0.54) Troponin-1 median 0 50 0 0 0 (25-75%) (0.0_ (50-359) (0.0-0.2 (0.0-0.2) (0.0-0.2) IU ng/ml 0.0) 11 - H-FABP plasma levels (OD measurement) in the AMI group were significantly higher than the respective level in the Control group (Table 2). The ANI group had a HFABP median level (range 25-75%) of 2.89 (2.70-3.0) while the Control group had a level of 0.25 (0.23-0.27). The HFABP plasma level in the WD group was between the slopes of the AMI and the Control groups. H-FABP median (range 25-75%) level in the plasma WD group was 0.79 (0.74- 0.86). The sensitivity, spec-if;iclty, and predictive accuracy of H-FABP levels beyond the cut off value of 0.30 were 100%, 100% and 100% respectively. To confirm differences in H-FABP concentrations between AMI and Control groups, Troponin-1 was assayed. In addition, in order to discriminate AMI and WD, they were also assayed on WD samples. The Troponin-1 concentration was measured in each group. Troponin-I concentration in the AMI group was significantly (p>0.01) higher than in the Control group.
D-iscusslon The above results indicate that H-FABP is a potential marker for WD diagnosis. Since H-MBP was presented as a marker of acute myocardial infarction a few years ago, WD and AMI had to be discriminated by another AMI biochemical marker such as Troponin-I or CKMB. Aúter the discrimination of AMI for WD patient, the serum as well as the CSF H-FABP concentration could be used as a specific marker of WD.
In the present study, H-FABP assay allowed a sensitivity, a specificity and a predictive accuracy (OD response > 0.30) of 100%. These values were significantly higher than those of 14-3-3 protein for detection of WD as the three dementia patients were positive after immilnoblottúng detection. The specIficity of 14-3-3 is not limited to WD but includes also Alzheimer's dementia, cerebral complications from head injury and some other forms of dementia.
Acute myocardial infarction is diagnosed with the help of biochemical marker assays such as cardiac Troponin-I, Creatine-Kinase MB, myoglobin and recently HFABP assay. The H-FABP level for WD could interfere with AMI and discrimination between AMI and WD was made with the use of other AMI markers.
Each of the above cited publications is herein incorporated by reference to the extent to which it is relied on herein.
The following claims define some important is embodiments of the invention, but should not be construed as detracting from the generality of the concepts hereinbefore set forth.
13 -
Claims (8)
1. A method of diagnostic assay for a transmissible spongiform encephalopathy (TSE) or the possibility thereof in a sample of body fluid taken from a patient suspected of suffering from the TSE, which comprises determining the concentration of heart or brain fatty acid binding protein (H-FABP or B-FABP) In the sample.
2. A method according to Claim 1, wherein the subject is a human and the concentration of H-FA.BP is determined in a first assay, whereby a positive result indicates either a WD or acute myocardúal infarction, and which further comprises carrying out a second diagnostic assay, for acute myocardial infarctúon (AMI) only, whereby a is positive result in the H-FABP assay and a negative result in the assay for AMI indicates that the patient is or might be suffering from a WD.
3. A method according to Claim 2, wherein the assay for AMI comprises determining the concentration of troponin-1 or creatine kúnase NB in plasma.
4. A method according to Claim 1, 2 or 3, wherein an antibody to H-FABP is used in the assay for H-FABP.
5. A method according to Claim 4, wherein the subject is a human patient and a mouse anti-human FABP monoclonal antibody is used.
6. A method according to any Claim 4 or 5, wherein the assay for H-FABP comprises a sandwich ELISA.
7. A method according to Claim 1, wherein B-FABP or an antibody thereto is used without any assay for AMI in combination therewith.
8. A method according to any preceding Claim, wherein the H-FABP or BFABP assay is carried out on a blood or serum sample.
Priority Applications (12)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0005683A GB2360089A (en) | 2000-03-10 | 2000-03-10 | Diagnostic assay for transmisible spongiform encephalopathies |
| GB0006064A GB0006064D0 (en) | 2000-03-10 | 2000-03-14 | Diagnostic assay for transmissable spongiform encephalopathies |
| CA002402314A CA2402314C (en) | 2000-03-10 | 2001-03-12 | Diagnostic assay for transmissible spongiform encephalopathies |
| AT01931527T ATE368858T1 (en) | 2000-03-10 | 2001-03-12 | METHOD FOR DIAGNOSING TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHIES |
| EP01931527A EP1261875B1 (en) | 2000-03-10 | 2001-03-12 | Diagnostic assay for transmissible spongiform encephalopathies |
| DE60129674T DE60129674T2 (en) | 2000-03-10 | 2001-03-12 | PROCESS FOR THE DIAGNOSIS OF TRANSMISSIBLE SPONGIFORMS ENCEPHALOPATHIES |
| DK01931527T DK1261875T3 (en) | 2000-03-10 | 2001-03-12 | Diagnostic analysis for transmissible spongiform encephalopathy |
| PCT/EP2001/002894 WO2001067108A2 (en) | 2000-03-10 | 2001-03-12 | Diagnostic assay for transmissible spongiform encephalopathies |
| AU5828201A AU5828201A (en) | 2000-03-10 | 2001-03-12 | Diagnostic assay for transmissible spongiform encephalopathies |
| JP2001566030A JP4575635B2 (en) | 2000-03-10 | 2001-03-12 | Diagnostic assays for infectious spongiform encephalopathy |
| AU2001258282A AU2001258282B2 (en) | 2000-03-10 | 2001-03-12 | Diagnostic assay for transmissible spongiform encephalopathies |
| US10/238,557 US7368247B2 (en) | 2000-03-10 | 2002-09-10 | Diagnostic assay for transmissible spongiform encephalopathies |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0005683A GB2360089A (en) | 2000-03-10 | 2000-03-10 | Diagnostic assay for transmisible spongiform encephalopathies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| GB0005683D0 GB0005683D0 (en) | 2000-05-03 |
| GB2360089A true GB2360089A (en) | 2001-09-12 |
Family
ID=9887282
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB0005683A Withdrawn GB2360089A (en) | 2000-03-10 | 2000-03-10 | Diagnostic assay for transmisible spongiform encephalopathies |
| GB0006064A Ceased GB0006064D0 (en) | 2000-03-10 | 2000-03-14 | Diagnostic assay for transmissable spongiform encephalopathies |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB0006064A Ceased GB0006064D0 (en) | 2000-03-10 | 2000-03-14 | Diagnostic assay for transmissable spongiform encephalopathies |
Country Status (1)
| Country | Link |
|---|---|
| GB (2) | GB2360089A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2379737A (en) * | 2001-09-05 | 2003-03-19 | Univ Geneve | Diagnostic method for spongiform encephalopathy disease |
| JP2013092538A (en) * | 2005-07-14 | 2013-05-16 | Univ De Geneve | Diagnostic method for brain damage-related disorder |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998023962A1 (en) * | 1996-11-23 | 1998-06-04 | Proteome Sciences Plc | Diagnosis of prion diseases |
| EP0861900A1 (en) * | 1997-02-21 | 1998-09-02 | Erziehungsdirektion Of The Canton Zurich | Immunological detection of prions |
| WO1998045440A1 (en) * | 1997-04-08 | 1998-10-15 | Incyte Pharmaceuticals, Inc. | Human fatty acid binding protein |
-
2000
- 2000-03-10 GB GB0005683A patent/GB2360089A/en not_active Withdrawn
- 2000-03-14 GB GB0006064A patent/GB0006064D0/en not_active Ceased
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998023962A1 (en) * | 1996-11-23 | 1998-06-04 | Proteome Sciences Plc | Diagnosis of prion diseases |
| EP0861900A1 (en) * | 1997-02-21 | 1998-09-02 | Erziehungsdirektion Of The Canton Zurich | Immunological detection of prions |
| WO1998045440A1 (en) * | 1997-04-08 | 1998-10-15 | Incyte Pharmaceuticals, Inc. | Human fatty acid binding protein |
Non-Patent Citations (2)
| Title |
|---|
| J. Neurochem.; Vol 66 (4), pp 1648-1656 (1996). Myers-Payne et al * |
| Mol. Cell. Biochem.; Vol 198(1&2), pp 69-78 (1999). Pu et aL * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2379737A (en) * | 2001-09-05 | 2003-03-19 | Univ Geneve | Diagnostic method for spongiform encephalopathy disease |
| JP2013092538A (en) * | 2005-07-14 | 2013-05-16 | Univ De Geneve | Diagnostic method for brain damage-related disorder |
Also Published As
| Publication number | Publication date |
|---|---|
| GB0006064D0 (en) | 2000-05-03 |
| GB0005683D0 (en) | 2000-05-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2402314C (en) | Diagnostic assay for transmissible spongiform encephalopathies | |
| AU2001258282A1 (en) | Diagnostic assay for transmissible spongiform encephalopathies | |
| EP0891553B1 (en) | A method of detecting transmissible spongiform encephalopathies | |
| MXPA03009744A (en) | Non focussed method of exciting and controlling acoustic fields in animal body parts. | |
| WO2008070229A2 (en) | Detection of pathogenic aggregates of protein in a sample by homologous elisa | |
| WO1998040748A1 (en) | Diagnosing neurologic disorders | |
| CA2393127C (en) | Diagnostic assay for stroke | |
| KR20030032893A (en) | Antibodies for specifically detecting pathogenic prions of human origin, and detection methods carried out using these antibodies | |
| US20160131663A1 (en) | Biomarker for psychiatric and neurological disorders | |
| GB2319607A (en) | Detection of prion proteins in mononuclear cells | |
| GB2360089A (en) | Diagnostic assay for transmisible spongiform encephalopathies | |
| US20060166192A1 (en) | Detection of protease-resistant prion protein following a spontaneous transformation reaction | |
| EP2653872A1 (en) | Biomarker for amyloid-beta -related neurological disorders | |
| US20040175775A1 (en) | Method of detecting PrPsc in eye fluid | |
| CA1302250C (en) | Diagnostic for alzheimer's disease | |
| JP3768165B2 (en) | Method and kit for measuring anti-carpastatin antibody | |
| JP3938239B2 (en) | Demyelinating disease detection method | |
| CA3245623A1 (en) | Diagnosis of congenital heart block | |
| Green | CK-MB Measurements by Immunoassay | |
| CA2237739A1 (en) | A specific and sensitive method to detect prpsc in peripheral blood using a capture-immunosorbent assay-polymerase chain reaction (prp-immuno-pcr) | |
| KR20200077779A (en) | A composition for predicting a risk of neurodegenerative diseases and a method for predicting neurodegenerative diseases using the same | |
| CA2118709A1 (en) | Enzyme capture assay |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WAP | Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1) |